• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    ▼
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact
Science

Science

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact

Publications

Publications

Epidemiology and patient journey in inclusion body myositis: A machine learning methodology applied to claims data in the United States

April 9, 2025

Epidemiology and patient journey in inclusion body myositis: A machine learning methodology applied to claims data in the United States
AAN 2025 Poster

>>View Poster
>>Plain Language Summary

Pharmacokinetics, pharmacodynamics, and safety profile of ulviprubart: Results from a 48-week, open-label, phase 1 study in patients with inclusion body myositis

April 9, 2025

Pharmacokinetics, pharmacodynamics, and safety profile of ulviprubart: Results from a 48-week, open-label, phase 1 study in patients with inclusion body myositis
AAN 2025 Poster

>>View Poster
>>Plain Language Summary

Selective Depletion of KLRG1+ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), GCOM 2022 Poster

June 6, 2022

Selective Depletion of KLRG1+ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), GCOM 2022 Poster

>>View Poster

Goel et al., Depletion of KLRG1+ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), ACR 2021 Poster

October 22, 2021

Goel et al., Depletion of KLRG1+ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), ACR 2021 Poster

>>View Poster

Greenberg et al., Highly differentiated cytotoxic T cells in inclusion body myositis, Brain 2019 Sep 1;142(9):2590-2604

September 1, 2019

Greenberg et al., Highly differentiated cytotoxic T cells in inclusion body myositis, Brain 2019 Sep 1;142(9):2590-2604

>>View Publication

Greenberg, Inclusion body myositis: clinical features and pathogenesis, Nat Rev Rheumatol, 2019 May;15(5):257-272

May 1, 2019

Greenberg, Inclusion body myositis: clinical features and pathogenesis, Nat Rev Rheumatol, 2019 May;15(5):257-272

>>View Publication

Greenberg et al., Association of inclusion body myositis with T cell large granular lymphocytic leukaemia, Brain 2016 May;139(Pt 5):1348-60

February 26, 2016

Greenberg et al., Association of inclusion body myositis with T cell large granular lymphocytic leukaemia, Brain 2016 May;139(Pt 5):1348-60

>>View Publication

Privacy Site Credits Terms of Use

© 2025 Abcuro